Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Clinton Drug Price Board, 23 Years Later

Executive Summary

Hillary Clinton is reviving an idea she first endorsed in 1993: a drug price oversight board, but the focus has changed. While the pharma industry isn’t about to embrace any federal oversight board, the new Clinton plan is a lot less threatening than the old one.

You may also be interested in...



“B” Best? Handicapping The Democratic Field For Pharma

Drug pricing is bound to be a dominant theme in the 2020 Democratic primaries and US Presidential election. But there are some differences in the crowded field of candidates, including several who are more likely to emphasis protecting innovation alongside controlling prices.  

Dems' 'Better Deal' Would Create Drug Price Gouging 'Enforcer'

Plan would empower new agency to investigate and potentially fine drug manufacturers that make unjustified price increases.

Pricing Transparency Policies Not Suited To Generics, GPhA Argues

Legislation like FAIR drug pricing bill, which requires sponsors to justify price increases over 10%, could ultimately discourage generic competition since it could burden ANDA sponsors for even small dollar increases, GPhA CEO Davis argues.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS119083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel